ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study

Chung, Cheuk To; Lakhani, Ishan; Chou, Oscar Hou In; Lee, Teddy Tai Loy; Dee, Christopher; Ng, Kendrick; Wong, Wing Tak; Liu, Tong; Lee, Sharen; Zhang, Qingpeng; Cheung, Bernard Man Yung; Tse, Gary*; Zhou, Jiandong*univ hong kong; new; chinese univ hong kong; 2; tianjin med univ
Cancer Medicine2023-6DOI: 10.1002/cam4.5927
3被引8阅读
引用收藏
分享

摘要

BackgroundCancer is currently the second leading cause of death globally. There is much uncertainty regarding the comparative risks of new-onset overall cancer and pre-specified cancer for Type 2 diabetes mellitus (T2DM) patients on sodium-glucose cotransporter 2 inhibitors (SGLT2I) versus DPP4I.Methods: This population-based cohort study patients included patients who were diagnosed with T2DM and administered either SGLT2 or DPP4 inhibitors between 1 January 2015 and 31 December 2020 in public hospitals of Hong Kong.Results: This study included 60,112 T2DM patients (mean baseline age: 62.1 +/- 12.4 years, male: 56.36%), of which 18,167 patients were SGLT2I users and 41,945 patients were dipeptidyl peptidase 4 inhibitor (DPP4I) users. Multivariable Cox regression found that SGLT2I use was associated with lower risks of all-cause mortality (HR: 0.92; 95% CI: 0.84-0.99; p= 0.04), cancer-related mortality (HR: 0.58; 95% CI: 0.42-0.80; p <= 0.001) and new diagnoses of any cancer (HR: 0.70; 95% CI: 0.59-0.84; p <= 0.001). SGLT2I use was associated with a lower risk of new-onset breast cancer (HR: 0.51; 95% CI: 0.32-0.80; p <= 0.001), but not of other malignancies. Subgroup analysis on the type of SGLT2I, dapagliflozin (HR: 0.78; 95% CI: 0.64-0.95; p = 0.01) and ertugliflozin (HR: 0.65; 95% CI: 0.43-0.98; p = 0.04) use was associated with lower risks of new cancer diagnosis. Dapagliflozin use was also linked to lower risks of breast cancer (HR: 0.48; 95% CI: 0.27-0.83; p = 0.001).Conclusion: Sodium-glucose cotransporter 2 inhibitor use was associated with lower risks of all-cause mortality, cancer-related mortality and new-onset overall cancer compared to DPP4I use after propensity score matching and multivariable adjustment.

学科与关键词

关键词
RISKMETFORMINDAPAGLIFLOZINMETAANALYSIS
相关
加载中…
  • Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
    Zhou, Jiandong; Liu, Xuejin; Chou, Oscar Hou-In; Li, Lifang; Lee, Sharen; Wong, Wing Tak; Zhang, Qingpeng; Chang, Carlin; Liu, Tong; Tse, Gary; Jing, Fengshi*; Cheung, Bernard Man Yung*RHEUMATOLOGY, 2023, 62(4): 1501-1510.被引 12
  • Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
    Lee, Sharen; Zhou, Jiandong; Leung, Keith Sai Kit; Wai, Abraham Ka Chung; Jeevaratnam, Kamalan; King, Emma; Liu, Tong; Wong, Wing Tak; Chang, Carlin; Wong, Ian Chi Kei; Cheung, Bernard Man Yung; Tse, Gary*; Zhang, Qingpeng*Cardiovascular Drugs and Therapy, 2023, 37(3): 561-569.被引 18
  • Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users
    Zhou, Jiandong; Lee, Sharen; Leung, Keith Sai Kit; Wai, Abraham Ka Chung; Liu, Tong; Liu, Ying; Chang, Dong; Wong, Wing Tak; Wong, Ian Chi Kei; Cheung, Bernard Man Yung; Zhang, Qingpeng*; Tse, Gary*ESC Heart Failure, 2022, 9(2): 1388-1399.被引 13
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Medicine
发表日期
2023-06
卷期
第 12 卷, 第 11 期
页码
12299-12315
DOI
10.1002/cam4.5927
语言
ENGLISH
成果收录
SCIE

作者

  • C

    Chung, Cheuk To (第一作者)

  • L

    Lakhani, Ishan

查看全部 13 位作者收起作者
  • C

    Chou, Oscar Hou In

    univ hong kong

  • L

    Lee, Teddy Tai Loy

  • D

    Dee, Christopher

    new

  • N

    Ng, Kendrick

  • W

    Wong, Wing Tak

    chinese univ hong kong

  • L

    Liu, Tong

    2 · tianjin med univ

  • L

    Lee, Sharen

  • Z

    Zhang, Qingpeng

  • C

    Cheung, Bernard Man Yung

    univ hong kong

  • T

    Tse, Gary (通讯)

    2 · tianjin med univ

  • Z

    Zhou, Jiandong (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417